Abstract 907P
Background
Pembro improved OS over SOC in patients (pts) with previously treated R/M HNSCC in the phase III KEYNOTE-040 study (NCT02252042). We present the associated exploratory biomarker results including TMB, PD-L1 CPS, and T-cell–inflamed gene signature (TcellinfGEP).
Methods
Pts with HNSCC who progressed during or after platinum-containing therapy for R/M disease, or whose disease recurred or progressed within 3-6 mo of prior multimodal platinum-containing therapy were randomly assigned 1:1 to pembro 200 mg Q3W or investigator’s choice of SOC. Association of TMB by WES, PD-L1 CPS (IHC 22C3 pharmDx), and TcellinfGEP by RNAseq with clinical response (ORR [logistical regression], PFS and OS [Cox model]) was evaluated within each treatment arm. The Spearman correlation was calculated between TMB, PD-L1 CPS, and TcellinfGEP, as continuous scores. Nominal significance was prespecified at P = 0.05 (pembro, 1-sided; SOC, 2-sided).
Results
Of 495 pts, 365 (184 pembro; 181 SOC) had WES samples, 476 (245 pembro; 231 SOC) had PD-L1 CPS results, and 313 (156 pembro; 157 SOC) had samples for RNAseq. TMB, PD-L1 CPS, and TcellinfGEP were all associated with improved ORR, PFS, and OS for pembro (P < 0.05); no associations were observed for SOC (P > 0.05). Additional biomarker analyses using prespecified cutpoints are shown in the table. Within the pembro arm, TMB was weakly correlated with PD-L1 CPS (r = 0.1) or TcellinfGEP (r = 0.01); PD-L1 CPS and TcellinfGEP were moderately correlated (r = 0.49). Table: 907P
Biomarker analyses at prespecified cut points
| PFS HR (95% CI) | OS HR (95% CI) | |
| PD-L1 | ||
CPS ConclusionsIn this exploratory analysis of KEYNOTE-040, higher TMB, PD-L1 CPS, and TcellinfGEP were associated with improved outcomes for pembro in pts with R/M HNSCC, but were not prognostic for SOC. These results suggest utility of TMB, PD-L1 CPS, and TcellinfGEP in characterizing response to pembro in HNSCC and support continued research in earlier lines of therapy. Clinical trial identificationNCT02252042; release date: September 29, 2014. Editorial acknowledgementMedical writing and editorial assistance was provided by Mallory Campbell, PhD, and Robert Steger, PhD, of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. Legal entity responsible for the studyMerck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc. FundingFunding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc. DisclosureD. Soulieres: Financial Interests, Personal and Institutional, Advisory Board: Merck & Co, Inc, Adlai-Nortye, EMD-Serono; Financial Interests, Personal and Institutional, Research Grant: Merck & Co, Inc, Adlai-Nortye, EMD-Serono; Financial Interests, Personal and Institutional, Invited Speaker: Merck & Co, Inc, Adlai-Nortye; Financial Interests, Institutional, Research Grant: Incyte, GSK. C. Le Tourneau: Financial Interests, Personal, Advisory Board: MSD, BMS, Merck Serono, Roche, ALX Oncology, Seattle Genetics, Aveon, Immutep, Seagen, Meerus, Exscientia, MaxiVax, PCI Biotech, Nanobiotix, Onxeo. J. Machiels: Financial Interests, Institutional, Advisory Board, Travel Expenses, Research Funding: Pfizer, BMS, CureVac; Financial Interests, Institutional, Advisory Board, Research Funding: Roche, Bayer, Merck Serono, Serono, Boerhinger Ingelheim, Novartis, Incyte, Cue Biopharma, ALX Oncology, iTEOS, eTheRNA, NEKTAR, F-Star, Seagen, Genmab, Astellas, MSD, GSK, Merus; Financial Interests, Other, Travel Expenses: Amgen, Gilead, Sanofi; Financial Interests, Other, Data Safety Monitoring Board with Honoraria: Psioxus; Financial Interests, Personal, Other, Investigator and Study Coordinator: EORTC. B. Burtness: Financial Interests, Personal and Institutional, Advisory Board, Research Grant, Principal Investigator, Advisory Role: Yale School of Medicine. K.J. Harrington: Financial Interests, Institutional, Advisory Board: Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Merck, MSD, Pfizer, Replimune, Oncolys, Vyriad, Idera; Financial Interests, Institutional, Other, Honoraria for lectures: Amgen, AstraZeneca, BMS, Boehringer Ingelheim; Financial Interests, Institutional, Advisory Board, Advisory board for CD47 assets: Arch Oncology; Financial Interests, Institutional, Advisory Board, Development of DDR assets: ARTIOS; Financial Interests, Institutional, Advisory Board, Development of exosomal STING agonist: Codiak; Financial Interests, Institutional, Advisory Board, Development of oncolytic adenovirus: PsiVac; Financial Interests, Institutional, Funding, Research: AstraZeneca, Boehringer Ingelheim, MSD; Financial Interests, Institutional, Funding, Development of oncolytic HSV platform: Replimune; Non-Financial Interests, Leadership Role, Chair of Steering Committee: ART NET; Non-Financial Interests, Other, Member of Global Steering Committee: MR - Linac. J. Shen, J. Tao, A. Webber, A. Vajdi: Financial Interests, Personal, Stocks/Shares: Merck & Co, Inc.; Financial Interests, Personal, Full or part-time Employment: Merck & Co, Inc. A. Loboda: Financial Interests, Personal, Full or part-time Employment: MSD. N. Lerman: Financial Interests, Personal, Stocks/Shares: Merck & Co, Inc.; Financial Interests, Personal, Full or part-time Employment: Merck & Co, Inc. B. Gumuscu: Financial Interests, Personal, Full or part-time Employment: Merck & Co, Inc.; Financial Interests, Personal, Stocks/Shares: Merck & Co, Inc.; Financial Interests, Personal, Other, Travel: Merck & Co, Inc. L.F.L. Licitra: Financial Interests, Personal, Advisory Board, for expert opinion in advisory boards: AstraZeneca, Bayer, BMS, Eisai, MSD, Boehringer Ingelheim, Hoffmann-La Roche Ltd, Novartis, Roche, Debiopharm International SA, Sobi, Incyte Biosciences Italy srl, Doxa Pharma srl, Amgen, Nanobiotics, GSK; Financial Interests, Institutional, Research Grant, Funds received by my institution for clinical studies and research activities in which I am involved: AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, Hoffmann-La roche ltd, IRX Therapeutics, Medpace, Merck Serono, Merck Healthcare KGaA, MSD, Novartis, Pfizer, Roche, Adlai Nortye. Resources from the same session1046P - Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapyPresenter: Yi Hu Session: Poster session 03 Resources: Abstract 1047P - Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritisPresenter: Michel Obeid Session: Poster session 03 1048P - Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter studyPresenter: Danielle Delombaerde Session: Poster session 03 1049P - Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective studyPresenter: Mariam Shalaby Session: Poster session 03 1050P - Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAEPresenter: Sarah Roffeis Session: Poster session 03 1051P - Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitorsPresenter: Antoine Italiano Session: Poster session 03 Resources: Abstract 1052P - Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signaturesPresenter: Elisabetta Nale Session: Poster session 03 1053P - The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based studyPresenter: Abdulrahman Alghabban Session: Poster session 03 1054P - CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatmentPresenter: Mariano Provencio Pulla Session: Poster session 03 1055P - Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancersPresenter: Annarita Avanzo Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|